5EzBXHjBoUfXbZbRaO6MsQqQnPtNfQpPtNeRoOqR8OqRpPNZoPpRuOoOpPBERNSTEIN31 May 2026SOCIETEGENERALE GROUPUsBiopharmaceuticalsUS Biopharma: NSCLC read-across from the Ivo & plenary data atASCO - MRK. BMY.PFE.ABBVAftertheASCOplenary,wetakethisopportunitytoask-whatdoesthisSMMT/AkesoCourtneyBreen+19173448407(coveredbyWalch/Liang)datameanforotherplayers in the lunglandscape?courtney.breen@bernsteinsg.comWhatdidwelearn fromHARMONi-6?Ivonescimab+chemodemonstrateda 0.66OSWoody PolglaseHR(4mobenefit)comparedwithTisle+chemo in1LsquamousmNSCLC Chinesepatients.+1917344 8314Significance was demonstratedacross both>1%and<1%PD-L1TPS subgroups,woody.polglase@bernsteinsg.comhoweverthebenefit wasleastevidentforthe>65yearspatientpopulation.WhatLouisa Qiuquestions remain?Is this a squamous-specific effect? A China-only effect? Do the elderly+1917344 8495have no benefit?Is this an Ivo-specific outcome, or does this provide confidence in thelouisa.qiu@bernsteinsg.comentirety of the PD1xVEGFclass? And, is the OS improvement durable?Today's data doesn'tyet do enough to convince us that the PD1xVEGF class will be successful in demonstratingSpecialist Salessuperiority to the Keytruda-heavy SoC in 1L mNSCLC globally, but it is still a possibility.Christian Moore+19173448555For MRK's current business -if PD1xVEGFperformance is replicated in the squamouschristian.moore@bernsteinsg.comglobal population, with continued poor performance in the elder-group-this coulddisrupt up to~3% of total Keytruda revenue from28.If PD1xVEGF OS superiority is alsodemonstrated in non-squamous regardless of TPS stratification,then we could anticipate~7%moreKeytruda revenue couldbeat risk from29by ivo/thePD1xVEGFclass(Exhibit 1).However,displacement of the Keytruda backbone will be reliant on physicianperception of AE management &durability of the OS signal &five yeardata isunlikely tobe available until beyond the end of the decade.TROP-2ADCs (esp.for MRK &AZN/DS - covered by Smith & Sogi)-we've seen strong data from sac-TMT in Opti-TROP-O5,howeverthis only comparedwithmonotherapyKeytruda &only in a Chinese population.We like the TROFUSE-023 trial design in sq.1Lpatients, but are looking forward tounderstanding if MRK will consider expanding development,given signals in non sq.fromthis Chinese Study. And for others with PD1xVEGFs of their own - BMY, PFE, ABBV,MRK -despite meaningful variability in the molecules (PD1 vs PDL1 targeting & VEGFvs PD(L)1 positioning on the mAb)-we aren't yet seeing meaningful variability in clinicaloutcomes.ORR andAEprofilesfor Pumitamig (BMY/BNTX-covered byWalch) &PFE'sPF4404 appear remarkably similar.We may again be in an environment (like the PD(L)1s)where trial design,trial execution,stratification &combination choices will determineclinical and commercial success.We also note that Pfizermgmt seemed tosuggestthattheir new all-comers SV-ADC trial may be in combination with'4404 -meaning they maybethefirstto advancea novel-novel 1L mNSCLC combination.The only standing ovationinducing-data at...